The phase 3 EURIDIS and ADONIS studies evaluated dronedarone for atrial fibrillation (AF)/atrial flutter (AFL) recurrence in patients with non-permanent AF. Here we assessed whether patient characteristics and/or treatment outcomes in these studies differed based on need for
BACKGROUND
Dronedarone has been shown to reduce cardiovascular hospitalizations or death in patients with atrial fibrillation (AF) and additional risk factors. This post hoc exploratory analysis examines its effects in the subgroup of lone AF patients.
RESULTS
Individual data from patients with lone